Morgan Stanley
MRNS

Morgan Stanley’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Morgan Stanley’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,299,229
Closed -$1.77M – 8341
2024
Q4 		$1.77M Buy
3,299,229
+3,134,161
+1,899% +$2.18M ﹤0.01% 4792
2024
Q3 		$291K Sell
165,068
-14,744
-8% -$20.6K ﹤0.01% 5616
2024
Q2 		$210K Sell
179,812
-228,251
-56% -$571K ﹤0.01% 5652
2024
Q1 		$3.69M Sell
408,063
-759,527
-65% -$7.38M ﹤0.01% 4161
2023
Q4 		$12.7M Buy
1,167,590
+1,120,443
+2,376% +$8.4M ﹤0.01% 3727
2023
Q3 		$380K Sell
47,147
-51,624
-52% -$429K ﹤0.01% 5294
2023
Q2 		$1.07M Sell
98,771
-23,146
-19% -$198K ﹤0.01% 4785
2023
Q1 		$841K Buy
121,917
+20,656
+20% +$130K ﹤0.01% 4952
2022
Q4 		$403K Buy
101,261
+66,925
+195% +$329K ﹤0.01% 5346
2022
Q3 		$227K Sell
34,336
-71,611
-68% -$441K ﹤0.01% 5672
2022
Q2 		$511K Buy
105,947
+83,906
+381% +$510K ﹤0.01% 5414
2022
Q1 		$207K Sell
22,041
-16,117
-42% -$160K ﹤0.01% 5907
2021
Q4 		$453K Buy
38,158
+14,941
+64% +$173K ﹤0.01% 5609
2021
Q3 		$263K Sell
23,217
-60,944
-72% -$838K ﹤0.01% 5859
2021
Q2 		$1.51M Buy
84,161
+15,593
+23% +$251K ﹤0.01% 4838
2021
Q1 		$1.06M Buy
68,568
+34,343
+100% +$497K ﹤0.01% 4697
2020
Q4 		$417K Buy
34,225
+18,153
+113% +$253K ﹤0.01% 5191
2020
Q3 		$206K Buy
16,072
+9,274
+136% +$80K ﹤0.01% 5102
2020
Q2 		$70K Buy
6,798
+3,385
+99% +$31.1K ﹤0.01% 5551
2020
Q1 		$28K Sell
3,413
-14,102
-81% -$122K ﹤0.01% 5698
2019
Q4 		$151K Buy
17,515
+13,082
+295% +$73.4K ﹤0.01% 5516
2019
Q3 		$27K Sell
4,433
-42,539
-91% -$344K ﹤0.01% 5931
2019
Q2 		$780K Buy
46,972
+44,332
+1,679% +$770K ﹤0.01% 4362
2019
Q1 		$44K Sell
2,640
-11,388
-81% -$164K ﹤0.01% 5726
2018
Q4 		$161K Sell
14,028
-740
-5% -$15K ﹤0.01% 5369
2018
Q3 		$591K Sell
14,768
-8,199
-36% -$233K ﹤0.01% 4898
2018
Q2 		$650K Buy
22,967
+19,756
+615% +$438K ﹤0.01% 4920
2018
Q1 		$49K Buy
+3,211
New +$76.4K ﹤0.01% 5885
2017
Q4 		– Sell
-70
Closed -$2K – 6687
2017
Q3 		$2K Sell
70
-54
-44% -$605 ﹤0.01% 6411
2017
Q2 		$1K Buy
+124
New +$670 ﹤0.01% 6531
2017
Q1 		– Sell
-2,712
Closed -$11K – 6628
2016
Q4 		$11K Buy
2,712
+2,437
+886% +$11.3K ﹤0.01% 6136
2016
Q3 		$2K Sell
275
-25
-8% -$169 ﹤0.01% 6376
2016
Q2 		$1K Buy
+300
New +$5.53K ﹤0.01% 6455
2016
Q1 		– Sell
-56
Closed -$2K – 6756
2015
Q4 		$2K Sell
56
-17,001
-100% -$499K ﹤0.01% 6517
2015
Q3 		$569K Buy
17,057
+12,914
+312% +$729K ﹤0.01% 4518
2015
Q2 		$192K Sell
4,143
-4,179
-50% -$156K ﹤0.01% 5266
2015
Q1 		$299K Buy
+8,322
New +$365K ﹤0.01% 4974
2014
Q4 		– Sell
-380
Closed -$10K – 6696
2014
Q3 		$10K Buy
+380
New +$11.7K ﹤0.01% 6199

Morgan Stanley's MRNS Position: Q1 2025 in Review

Morgan Stanley sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2025, closing a stake of 3,299,229 shares — an estimated $1.77M sold.

Morgan Stanley first reported a position in MRNS in Q3 2014 and held it in 38 quarters. The position peaked at $12.7M in Q4 2023. 0 funds tracked by Wall St. Rank hold MRNS as of Q1 2025.

  • Morgan Stanley reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2025 after selling out during the quarter.
  • Morgan Stanley sold 3,299,229 Marinus Pharmaceuticals, Inc shares in Q1 2025, an estimated $1.77M.
  • Morgan Stanley first reported a position in Marinus Pharmaceuticals, Inc in Q3 2014 and held it in 38 quarters.
  • Morgan Stanley's Marinus Pharmaceuticals, Inc position peaked at $12.7M in Q4 2023.
  • 0 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2025.

Based on Morgan Stanley's 13F filing for Q1 2025, filed 15 May 2025.